Back to Results
First PageMeta Content
Nephrology / Gadopentetic acid / Gadolinium / Gadodiamide / Magnetic resonance imaging / Pentetic acid / Schering AG / Gadoteridol / Contrast medium / Chemistry / Matter / Nephrogenic systemic fibrosis


U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived
Add to Reading List

Open Document

File Size: 2,18 MB

Share Result on Facebook

City

Gd / Gadolinium / /

Company

AES / Bayer / Bayer Schering Pharma / /

Event

FDA Phase / Product Issues / /

Facility

PHARMACY BULK PACKAGE AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page / PHARMACY BULK PACKAGE / /

IndustryTerm

chemical principles / endogenous trace metal levels / contrast-enhanced magnetic resonance imaging / Chemical structures / /

MedicalCondition

Nephrogenic Systemic Fibrosis / CMD / dissociation / /

Organization

Possible Association / National Science Foundation / U.S. Food and Drug Administration / i.v. administration / /

Person

MRI NDA NFD NMR NOAEL / /

Position

General / /

Product

Magnevist / DTPA / Omniscan / Calcium Chloride / rats / Copper Deoxyribonucleic Acid / /

Technology

Pharmacokinetics / Spectroscopy / X-ray / magnetic resonance imaging / tomography / MRI / /

SocialTag